Missed the webinar? Here are Investing.com’s top 10 stock picks for 2026
DUBLIN - Bank of America Corporation has disclosed a 3.024% stake in Avadel Pharmaceuticals plc, according to a regulatory filing published Tuesday.
The disclosure, made under Irish Takeover Panel rules, shows the financial institution holds 2,945,270 relevant securities in the pharmaceutical company as of December 1, 2025. This includes 2,804,362 ordinary shares owned or controlled, representing approximately 2.879% of the company, and 140,908 cash-settled derivatives accounting for 0.145%.
The filing also revealed Bank of America has short positions totaling 1,875,143 securities, equivalent to 1.925% of Avadel’s shares. These short positions consist of 1,028,390 relevant securities owned or controlled and 846,753 cash-settled derivatives.
The disclosure documented numerous transactions conducted on December 1, including multiple purchases of Avadel common shares at prices ranging from $21.37 to $21.55 per share. The largest single purchase was 1,612 shares at $21.42.
Bank of America also reported several sales of Avadel shares on the same day, with the largest being 12,986 shares sold at $21.42 per share.
The filing was made in compliance with Rule 8.3 of the Irish Takeover Panel Act, which requires disclosure of interests representing 1% or more in companies involved in potential takeover situations.
The information was provided through a regulatory news service filing, as required by the London Stock Exchange for primary information providers in the United Kingdom.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.